Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 66

Sort by

Sort Order Select

Journal Articles

Risk Factors and Cardiovascular Disease (CVD) Related Outcomes in Hospitalized Patients with Hemophilia 10 Year Follow up

Jonathan R Day, MD PharmD, Ashwin Gupta, Calvin Abro, MD, Kyungsuk Jung, MDMPH, Lakshmanan Krishnamurti, MD, Clifford Takemoto, MD, Ruchika Goel, MD MPH

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-136486

Published: 2020

Journal Articles

Resolution of Serious Vaso-Occlusive Pain Crises and Reduction in Patient-Reported Pain Intensity: Results from the Ongoing Phase 1/2 HGB-206 Group C Study of LentiGlobin for Sickle Cell Disease (bb1111) Gene Therapy

Alexis A. Thompson, MD, Mark C. Walters, MD, Markus Y Mapara, MD PhD, Janet L. Kwiatkowski, MD MSCE, Lakshmanan Krishnamurti, MD, Banu Aygun, MD, Kimberly A. Kasow, DO, Stacey Rifkin-Zenenberg, DO, Manfred Schmidt, PhD, Jay DelCarpini, Francis J. Pierciey, Jr., Alexandra L. Miller, Meghan E. Gallagher, MSc, Ren Chen, Sunita Goyal, MD, Julie Kanter, MD, John F. Tisdale, MD

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-134940

Published: 2020

Journal Articles

Improvements in Health-Related Quality of Life for Patients Treated with LentiGlobin for Sickle Cell Disease (bb1111) Gene Therapy

Julie Kanter, MD, John F. Tisdale, MD, Markus Y Mapara, MD PhD, Janet L. Kwiatkowski, MD MSCE, Lakshmanan Krishnamurti, MD, Ren Chen, Meghan E. Gallagher, MSc, Yuchen Ding, PhD, Sunita Goyal, MD, Clark Paramore, MPH, Alexis A. Thompson, MD, Mark C. Walters, MD

Blood (2020) 136 (Supplement 1): 10.

https://doi.org/10.1182/blood-2020-136193

Published: 2020

Journal Articles

Exploring the Drivers of Potential Clinical Benefit in Initial Patients Treated in the Hgb-206 Study of Lentiglobin for Sickle Cell Disease (SCD) Gene Therapy

Mark C. Walters, MD, John F. Tisdale, MD, Janet L. Kwiatkowski, MD MSCE, Lakshmanan Krishnamurti, MD, Markus Y. Mapara, MD PhD, Manfred Schmidt, PhD, Alexandra L. Miller, Francis J. Pierciey, Jr., Wenmei Huang, PhD MS, Jean-Antoine Ribeil, MD PhD, Julie Kanter, MD, Alexis A. Thompson, MD MPH

Blood (2019) 134 (Supplement_1): 2061.

https://doi.org/10.1182/blood-2019-128814

Published: 2019

Journal Articles

Preliminary Results of a Phase 1/2 Clinical Study of Zinc Finger Nuclease-Mediated Editing of BCL11A in Autologous Hematopoietic Stem Cells for Transfusion-Dependent Beta Thalassemia

Angela R. Smith, MD MS, Gary J. Schiller, MD, Gregory M Vercellotti, MD, Janet L. Kwiatkowski, MD MSCE, Lakshmanan Krishnamurti, MD, Erica B. Esrick, MD, David A. Williams, MD, Weston P. Miller, MD, Adrian Woolfson, MD PhD, Mark C. Walters, MD

Blood (2019) 134 (Supplement_1): 3544.

https://doi.org/10.1182/blood-2019-125743

Published: 2019

Journal Articles

Transcranial Doppler Screening in Children with Sickle Cell Anemia Is Feasible in Central India and Reveals High Risk of Stroke

Dipty Jain, MD, Kavitha Ganesan, MBBS, Sati Sahota, Deepika S. Darbari, MD, Lakshmanan Krishnamurti, MD, Fenella Jane Kirkham, MD

Blood (2019) 134 (Supplement_1): 2279.

https://doi.org/10.1182/blood-2019-131416

Published: 2019

Journal Articles

Excellent Overall Survival and Low Incidence of Late Effects in Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Sickle Cell Disease: A Report from the Center for International Blood and Marrow Transplant Research (CIBMTR)

Elizabeth Stenger, MD, Rachel Phelan, MDMPH, Bronwen E. Shaw, MD PhD, Minoo Battiwalla, MD, Stephanie Bo-Subait, MPH, Ruta Brazauskas, PhD, David K. Buchbinder, MD MSHS, Betty K. Hamilton, MD, Shalini Shenoy, MD, Lakshmanan Krishnamurti, MD

Blood (2019) 134 (Supplement_1): 697.

https://doi.org/10.1182/blood-2019-128797

Published: 2019

Journal Articles

A Phase II Trial to Compare Allogeneic Transplant Vs. Standard of Care for Severe Sickle Cell Disease: Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Protocol 1503

Mary Eapen, MBBS, MS, Donna S Neuberg, ScD, Adam M. Mendizabal, MS, Kristen E. Stevenson, MS, Joseph H. Antin, MD, Nancy DiFronzo, PhD, Fuad A El Rassi, MD, Premal Lulla, MBBS, Edmund K. Waller, PhDMD, Jamie Garrison, Shannon Smith, MSN, Keith Sullivan, MD, Mark C. Walters, MD, Lakshmanan Krishnamurti, MD

Blood (2019) 134 (Supplement_1): 4592.

https://doi.org/10.1182/blood-2019-126793

Published: 2019

Journal Articles

Associated Co-Morbidities, Healthcare Utilization, and Mortality in Hospitalized Children and Adults with Hemophilia in the United States: Updated Nationally Representative Estimates and a Comparative Analysis

Ashwin Gupta, Abdul Hannan, MD, Ruby Maini, MD, Stephanie Bitner, Pharm D, Schuyler Stone, MD, Manjari Regmi, MD, Aaron Tobian, MD PhD, Cassandra D Josephson, MD, Lakshmanan Krishnamurti, MD, Clifford M. Takemoto, MD, Ruchika Goel, MD MPH

Blood (2019) 134 (Supplement_1): 4711.

https://doi.org/10.1182/blood-2019-123161

Published: 2019

Journal Articles

Resolution of Sickle Cell Disease Manifestations in Patients Treated with Lentiglobin Gene Therapy: Updated Results from the Phase 1/2 Hgb-206 Group C Study

Julie Kanter, MD, John F. Tisdale, MD, Markus Y. Mapara, MD PhD, Janet L. Kwiatkowski, MD MSCE, Lakshmanan Krishnamurti, MD, Manfred Schmidt, PhD, Alexandra L. Miller, Francis J. Pierciey, Jr., Wenmei Huang, PhD MS, Jean-Antoine Ribeil, MD PhD, Alexis A. Thompson, MD MPH, Mark C. Walters, MD

Blood (2019) 134 (Supplement_1): 990.

https://doi.org/10.1182/blood-2019-128894

Published: 2019

Journal Articles

Vaccination Adherence in Pediatric Patients Post-Hematopoietic Stem Cell Transplant

Kirshma Khemani, MD, Molly K Steele, Nitya Bakshi, MBBS, MS, Lakshmanan Krishnamurti, MD, Inci Yildirim, MD PhD MSc FAAP

Blood (2018) 132 (Supplement 1): 3406.

https://doi.org/10.1182/blood-2018-99-119283

Published: 2018

Journal Articles

Current Results of Lentiglobin Gene Therapy in Patients with Severe Sickle Cell Disease Treated Under a Refined Protocol in the Phase 1 Hgb-206 Study

John F. Tisdale, MD, Julie Kanter, MD, Markus Y. Mapara, MD PhD, Janet L. Kwiatkowski, MD, Lakshmanan Krishnamurti, MD, Manfred Schmidt, PhD, Alexandra L. Miller, Francis J. Pierciey, Jr., Weiliang Shi, PhD, Jean-Antoine Ribeil, MD PhD, Mohammed Asmal, MD PhD, Alexis A. Thompson, MD MPH, Mark C. Walters, MD

Blood (2018) 132 (Supplement 1): 1026.

https://doi.org/10.1182/blood-2018-99-113480

Published: 2018

Journal Articles

Outcomes for Initial Patient Cohorts with up to 33 Months of Follow-up in the Hgb-206 Phase 1 Trial

Julie Kanter, MD, John F. Tisdale, MD, Janet L. Kwiatkowski, MD, Lakshmanan Krishnamurti, MD, Markus Y. Mapara, MD PhD, Manfred Schmidt, PhD, Alexandra L. Miller, Francis J. Pierciey, Jr., Weiliang Shi, PhD, Jean-Antoine Ribeil, MD PhD, Mark C. Walters, MD, Alexis A. Thompson, MD MPH

Blood (2018) 132 (Supplement 1): 1080.

https://doi.org/10.1182/blood-2018-99-113477

Published: 2018

Journal Articles

Administration of Rimiducid Following Haploidentical BPX-501 Cells in Children with Malignant or Non-Malignant Disorders Who Develop Graft-Versus-Host-Disease (GvHD)

Reem Elkeky, MBBS, David A. Jacobsohn, MD, Rajni Agarwal, MD, Swati Naik, MBBS, Neena Kapoor, MD, Lakshmanan Krishnamurti, MD, Mary Slatter, MD, Federica Galaverna, MD, Pietro Merli, MD, Melissa Aldinger, PharmD, Franco Locatelli

Blood (2018) 132 (Supplement 1): 2207.

https://doi.org/10.1182/blood-2018-99-119792

Published: 2018

Journal Articles

Administration of BPX-501 Cells Following Aβ T and B-Cell-Depleted HLA Haploidentical HSCT (haplo-HSCT) in Children with Acute Leukemias

Franco Locatelli, Annalisa Ruggeri, MD PhD, Pietro Merli, MD, Swati Naik, MBBS, Rajni Agarwal, MD, Victor Aquino, MD, David A. Jacobsohn, MD, Waseem Qasim, MD PhD, Eneida R. Nemecek, MD, Lakshmanan Krishnamurti, MD, Deepa Manwani, MD, Melissa Kuhn, PharmD, Neena Kapoor

Blood (2018) 132 (Supplement 1): 307.

https://doi.org/10.1182/blood-2018-99-119481

Published: 2018

Journal Articles

The Influence of the Age of Adults with Sickle Cell Disease on the Uptake, Utilization and Efficacy of Hydroxyurea

Cynthia Sinha, PhD, Nitya Bakshi, MBBS, MS, Diana Ross, MSN, RN, Lakshmanan Krishnamurti, MD

Blood (2017) 130 (Supplement 1): 3421.

https://doi.org/10.1182/blood.V130.Suppl_1.3421.3421

Published: 2017

Journal Articles

Frequency of Vasocclusive Crises and the Relationship of Vitamin D Deficiency to the Frequency of Pain Crises in Children with Sickle Cell Disease in an Aboriginal Tribal Region in Gadchiroli, India

Dipty Jain, MD, Sanjana Jaiswal, MBBS, Nitya Bakshi, MBBS, MS, Lakshmanan Krishnamurti, MD

Blood (2017) 130 (Supplement 1): 3551.

https://doi.org/10.1182/blood.V130.Suppl_1.3551.3551

Published: 2017

Journal Articles

Development of a Multi-Center Cohort to Evaluate Long-Term Outcomes and Late Effects Following Hematopoietic Cell Transplantation for Sickle Cell Disease: A STAR Initiative

Elizabeth Stenger, MD, Allistair Abraham, MD, Curtis D Travers, MPH, Hemalatha G. Rangarajan, MD, Diane Hsu, MD, Sonali Chaudhury, MBBS,MD, Kimberly A. Kasow, DO, Michael J. Eckrich, MD MPH, Alexander I. Ngwube, MD, Julie Kanter, MD, Gregory M Guilcher, MDBSc,FRCPC, John T. Horan, MDMPH, Lakshmanan Krishnamurti, MD, Shalini Shenoy, MD

Blood (2017) 130 (Supplement 1): 3271.

https://doi.org/10.1182/blood.V130.Suppl_1.3271.3271

Published: 2017

Journal Articles

Increased Proportion of Sickle Cell Disease Patients Develop Cardiovascular Disease Risk Factors Following Successful Hematopoietic Cell Transplantation

Elizabeth Stenger, MD, Kirshma Khemani, MD, Diana Ross, MSN, RN, Lillian Meacham, MD, Courtney McCracken, PhD, Ann Haight, MD, Lakshmanan Krishnamurti, MD

Blood (2017) 130 (Supplement 1): 1999.

https://doi.org/10.1182/blood.V130.Suppl_1.1999.1999

Published: 2017

Journal Articles

Use of an Emergency Department-Based Intranasal Fentanyl Protocol for Vaso-Occlusive Episodes in Sickle Cell Disease: The Unanticipated Consequences

Kirshma Khemani, MD, Lankala Mahati Reddy, MD, Shabnam Jain, MD M.P.H, Amanda Mallino, April Zmitrovich, MSW, MPH, Bolanle Akinsola, MD, Lakshmanan Krishnamurti, MD, Claudia R. Morris, MD

Blood (2017) 130 (Supplement 1): 2264.

https://doi.org/10.1182/blood.V130.Suppl_1.2264.2264

Published: 2017

NARROW

Risk Factors and Cardiovascular Disease (CVD) Related Outcomes in Hospitalized Patients with Hemophilia 10 Year Follow up

Resolution of Serious Vaso-Occlusive Pain Crises and Reduction in Patient-Reported Pain Intensity: Results from the Ongoing Phase 1/2 HGB-206 Group C Study of LentiGlobin for Sickle Cell Disease (bb1111) Gene Therapy

Improvements in Health-Related Quality of Life for Patients Treated with LentiGlobin for Sickle Cell Disease (bb1111) Gene Therapy

Exploring the Drivers of Potential Clinical Benefit in Initial Patients Treated in the Hgb-206 Study of Lentiglobin for Sickle Cell Disease (SCD) Gene Therapy

Preliminary Results of a Phase 1/2 Clinical Study of Zinc Finger Nuclease-Mediated Editing of BCL11A in Autologous Hematopoietic Stem Cells for Transfusion-Dependent Beta Thalassemia

Transcranial Doppler Screening in Children with Sickle Cell Anemia Is Feasible in Central India and Reveals High Risk of Stroke

Excellent Overall Survival and Low Incidence of Late Effects in Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Sickle Cell Disease: A Report from the Center for International Blood and Marrow Transplant Research (CIBMTR)

A Phase II Trial to Compare Allogeneic Transplant Vs. Standard of Care for Severe Sickle Cell Disease: Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Protocol 1503

Associated Co-Morbidities, Healthcare Utilization, and Mortality in Hospitalized Children and Adults with Hemophilia in the United States: Updated Nationally Representative Estimates and a Comparative Analysis

Resolution of Sickle Cell Disease Manifestations in Patients Treated with Lentiglobin Gene Therapy: Updated Results from the Phase 1/2 Hgb-206 Group C Study

Vaccination Adherence in Pediatric Patients Post-Hematopoietic Stem Cell Transplant

Current Results of Lentiglobin Gene Therapy in Patients with Severe Sickle Cell Disease Treated Under a Refined Protocol in the Phase 1 Hgb-206 Study

Outcomes for Initial Patient Cohorts with up to 33 Months of Follow-up in the Hgb-206 Phase 1 Trial

Administration of Rimiducid Following Haploidentical BPX-501 Cells in Children with Malignant or Non-Malignant Disorders Who Develop Graft-Versus-Host-Disease (GvHD)

Administration of BPX-501 Cells Following Aβ T and B-Cell-Depleted HLA Haploidentical HSCT (haplo-HSCT) in Children with Acute Leukemias

The Influence of the Age of Adults with Sickle Cell Disease on the Uptake, Utilization and Efficacy of Hydroxyurea

Frequency of Vasocclusive Crises and the Relationship of Vitamin D Deficiency to the Frequency of Pain Crises in Children with Sickle Cell Disease in an Aboriginal Tribal Region in Gadchiroli, India

Development of a Multi-Center Cohort to Evaluate Long-Term Outcomes and Late Effects Following Hematopoietic Cell Transplantation for Sickle Cell Disease: A STAR Initiative

Increased Proportion of Sickle Cell Disease Patients Develop Cardiovascular Disease Risk Factors Following Successful Hematopoietic Cell Transplantation

Use of an Emergency Department-Based Intranasal Fentanyl Protocol for Vaso-Occlusive Episodes in Sickle Cell Disease: The Unanticipated Consequences

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only